Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 15, 2021 | |
Document Information Line Items | ||
Entity Registrant Name | iSign Solutions Inc. | |
Trading Symbol | ISIGN | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 6,321,980 | |
Amendment Flag | false | |
Entity Central Index Key | 0000727634 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Sep. 30, 2021 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q3 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 000-19301 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-2790442 | |
Entity Address, Address Line One | 2033 Gateway Place | |
Entity Address, Address Line Two | Suite 659 | |
Entity Address, City or Town | San Jose | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95110 | |
City Area Code | (650) | |
Local Phone Number | 802-7888 | |
Title of 12(b) Security | Common Stock | |
Security Exchange Name | NONE | |
Entity Interactive Data Current | Yes |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 108 | $ 26 |
Accounts receivable, net of allowance of $0 at September 30, 2021 and December 31, 2020, respectively | 128 | 100 |
Prepaid expenses and other current assets | 12 | 10 |
Total current assets | 248 | 136 |
Property and equipment, net | 5 | 5 |
Other assets | 5 | 5 |
Total assets | 258 | 146 |
Current liabilities: | ||
Accounts payable | 402 | 353 |
Short-term debt - related party | 1,398 | 1,065 |
Short-term debt – other | 1,542 | 1,807 |
Paycheck Protection Program | 123 | |
Accrued compensation | 77 | 82 |
Deferred compensation | 219 | 219 |
Other accrued liabilities | 1,381 | 1,141 |
Deferred revenue, current portion | 339 | 215 |
Total current liabilities | 5,358 | 5,005 |
Long-term debt - other | 45 | 90 |
Other long-term liabilities | 570 | 738 |
Total liabilities | 5,973 | 5,833 |
Commitments and contingencies | ||
Stockholders’ deficit: | ||
Common stock, $0.01 par value; 2,000,000 shares authorized; 6,322 shares issued and outstanding at September 30, 2021 and 5,762 at December 31, 2019 | 63 | 58 |
Treasury shares, 5 at September 30, 2021 and December 31, 2020, respectively | (325) | (325) |
Additional paid-in capital | 130,111 | 129,783 |
Accumulated deficit | (135,564) | (135,203) |
Total stockholders’ deficit | (5,715) | (5,687) |
Total liabilities and stockholders’ deficit | $ 258 | $ 146 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Accounts receivable, net of allowance (in Dollars) | $ 0 | $ 0 |
Common stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 2,000,000 | 2,000,000 |
Common stock, shares issued | 6,322 | 5,762 |
Common stock, shares outstanding | 6,322 | 5,762 |
Treasury shares | 5 | 5 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Revenue: | ||||
Product | $ 101 | $ 44 | $ 282 | $ 134 |
Maintenance | 181 | 198 | 528 | 525 |
Total revenue | 282 | 242 | 810 | 659 |
Cost of sales: | ||||
Product | 2 | 2 | 32 | 23 |
Maintenance | 21 | 27 | 51 | 63 |
Research and development | 156 | 126 | 436 | 446 |
Sales and marketing | 15 | 10 | 86 | 62 |
General and administrative | 130 | 397 | 446 | 816 |
Total operating costs and expenses | 324 | 562 | 1,051 | 1,410 |
Loss from operations | (42) | (320) | (241) | (751) |
Other income (expense), net | 125 | 373 | 125 | 425 |
Interest expense: | ||||
Related party | (35) | (30) | (97) | (77) |
Other | (50) | (52) | (147) | (144) |
Amortization of debt discount: | ||||
Related party | (1) | (1) | ||
Other | (1) | |||
Loss before income tax expense | (2) | (30) | (360) | (549) |
Income tax expense | (1) | (1) | ||
Net loss | $ (2) | $ (30) | $ (361) | $ (550) |
Basic and diluted net loss per common share (in Dollars per share) | $ 0 | $ (0.01) | $ (0.06) | $ (0.1) |
Weighted average common shares outstanding basic and diluted (in Shares) | 6,322 | 5,762 | 5,956 | 5,762 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($) $ in Thousands | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2019 | $ 58 | $ (325) | $ 129,651 | $ (134,675) | $ (5,291) |
Balance (in Shares) at Dec. 31, 2019 | 5,762 | 5 | |||
Stock-based compensation | 22 | 22 | |||
Net loss | (339) | (339) | |||
Balance at Mar. 31, 2020 | $ 58 | $ (325) | 129,673 | (135,014) | (5,608) |
Balance (in Shares) at Mar. 31, 2020 | 5,762 | 5 | |||
Stock-based compensation | 17 | 17 | |||
Warrant issued for services | 13 | 13 | |||
Net loss | (181) | (181) | |||
Balance at Jun. 30, 2020 | $ 58 | $ (325) | 129,703 | (135,195) | (5,759) |
Balance (in Shares) at Jun. 30, 2020 | 5,762 | 5 | |||
Stock-based compensation | 30 | 30 | |||
Warrants issued associated with other long-term liabilities | 160 | 160 | |||
Warrants issued in settlement of debt | 3 | 3 | |||
Net loss | (30) | (30) | |||
Balance at Sep. 30, 2020 | $ 58 | $ (325) | 129,896 | (135,225) | (5,596) |
Balance (in Shares) at Sep. 30, 2020 | 5,762 | 5 | |||
Balance at Dec. 31, 2020 | $ 58 | $ (325) | 129,783 | (135,203) | (5,687) |
Balance (in Shares) at Dec. 31, 2020 | 5,762 | 5 | |||
Stock-based compensation | 24 | 24 | |||
Net loss | (190) | (190) | |||
Balance at Mar. 31, 2021 | $ 58 | $ (325) | 129,807 | (135,393) | (5,853) |
Balance (in Shares) at Mar. 31, 2021 | 5,762 | 5 | |||
Stock-based compensation | 17 | 17 | |||
Settlement of deferred salary | $ 5 | 274 | 279 | ||
Settlement of deferred salary (in Shares) | 560 | ||||
Net loss | (169) | (169) | |||
Balance at Jun. 30, 2021 | $ 63 | $ (325) | 130,098 | (135,562) | (5,726) |
Balance (in Shares) at Jun. 30, 2021 | 6,322 | 5 | |||
Stock-based compensation | 13 | 13 | |||
Net loss | (2) | (2) | |||
Balance at Sep. 30, 2021 | $ 63 | $ (325) | $ 130,111 | $ (135,564) | $ (5,715) |
Balance (in Shares) at Sep. 30, 2021 | 6,322 | 5 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (361) | $ (550) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 3 | 309 |
Debt discount amortization | 2 | |
Warrant issued for services | 16 | |
Stock-based compensation | 54 | 69 |
Forgiveness of debt related to Paycheck Protection Program plus accrued interest | (125) | |
Forgiveness of debt related to accounts payable | (425) | |
Changes in operating assets and liabilities: | ||
Accounts receivable, net | (28) | (2) |
Prepaid expenses and other current assets | (2) | (9) |
Accounts payable | 49 | (291) |
Accrued compensation | (5) | 8 |
Other accrued and long-term liabilities | 353 | 339 |
Deferred revenue | 124 | (72) |
Net cash provided by (used) in operating activities | 62 | (606) |
Cash flows from investing activities: | ||
Acquisition of property and equipment | (3) | |
Net cash used in investing activities | (3) | |
Cash flows from financing activities: | ||
Proceeds from the issuance of short-term debt -related party | 211 | 183 |
Proceeds from the issuance of short-term debt -other | 45 | 300 |
Proceeds from the issuance of long-term debt –Paycheck Protection Program | 123 | |
Payment on short term debt - related party | (133) | |
Payment on short term debt - other | (100) | |
Net cash provided by financing activities | 23 | 606 |
Net decrease in cash and cash equivalents | 82 | |
Cash and cash equivalents at beginning of period | 26 | 25 |
Cash and cash equivalents at end of period | 108 | 25 |
Supplementary disclosure of cash flow information: | ||
Interest paid | 22 | 6 |
Income tax paid | 1 | 1 |
Non-cash financing and investing transactions: | ||
Value of warrants issued on other long-term liabilities | 15 | |
Settlement of accounts payable for issuance of short-term debt and long-term debt, other | $ 279 | $ 130 |
Nature of Business and Summary
Nature of Business and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Nature of Business and Summary of Significant Accounting Policies | 1. Nature of business and summary of significant accounting policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, and Sign-it® programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. Since March 11, 2020 states in the U.S., including California, where the Company is headquartered, have begun to open up as the result of the development of vaccines to thwart the spread of the virus. New variants of COVID-19 have surfaced around the world, including the United States which may cause additional closures of economies depending on how virulent the new strains are. New COVID-19 variant outbreaks may further disrupted supply chains and affected production and sales across a wide range of industries. The extent of the impact of new COVID-19 outbreaks on our operational and financial performance will depend on certain developments, including the duration and further spread of the outbreak, continued impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2021, the Company’s accumulated deficit was $135,564. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2021, the Company’s cash balance was $108. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). A modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange should be treated as an exchange of the original instrument for a new instrument. In addition, the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity should be measured. The effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange should be recognize on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company will evaluate ASU 2021-04 to determine what impact, if any, the adoption will have on the Company’s financial statements. Other Accounting Standards Updates issued in 2021 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows. |
Concentrations
Concentrations | 9 Months Ended |
Sep. 30, 2021 | |
Risks and Uncertainties [Abstract] | |
Concentrations | 2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue Total Revenue 2021 2020 2021 2020 2021 2020 Customer #1 88 % 70 % 40 % 18 % 38 % 21 % Customer #2 12 % 24 % - - - - Customer #3 - - - 10 % - 11 % Customer #4 - - 18 % 21 % 19 % 23 % Customer #5 - - 23 29 % 25 % 23 % Total concentration 100 % 94 % 81 % 78 % 82 % 78 % |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Net loss per share | 3. Net loss per share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the exercise of such options and warrants would be antidilutive: For the September 30, 2021 September 30, 2020 Common Stock subject to outstanding options 1,338 1,338 Common Stock subject to outstanding warrants 1,450 3,001 Common stock subject to outstanding convertible debt plus accrued interest 7,290 6,608 |
Debt
Debt | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Debt | 4. Debt Advances On February 17 and February 22, 2021, the Company repaid $30 and $30, respectively, of accounts receivable advances from unrelated parties along with $4 of accrued but unpaid advance fees. In addition, on March 31, 2021, the Company repaid $20 in accounts receivable advances to a related party. The advance fee of $1 was repaid on April 1, 2021. In March 2021, the Company received, from related parties, advances aggregating $25 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company agreed to repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The Company accrued $1 in advance fees recorded as interest expense on the Statement of Operations. In July 2021, the Company received $10,000 in cash from an affiliate as an advance against certain accounts receivable. The company accrued a 5% advance fee and recorded $500 as interest expense during the three months ended September 30, 2021. Upon collection of the accounts receivable the Company will repay the advance plus the 5% fee. In August and September 2021, the Company received $50,000 and $36,000, respectively in cash from an affiliate as advances against certain accounts receivable. The company accrued a 5% advance fees in August and September 2021, and recorded $4 as interest expense during the three months ended September 30, 2021. Upon collection of the accounts receivable the Company will repay the advances plus the 5% fee. Notes payable: On May 6, 2020, the Company received loan proceeds in the amount of approximately $123 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Company may apply for the loans and accrued interest forgiven after a period of either eight or twenty-four weeks, as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the period in question. Under the terms of the related promissory note, the unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. The Company applied for full loan and interest forgiveness. In September 2021 the Company received notification that the loan related to the Paycheck Protection Program had been forgiven in full. The Company record $125 of other income on the Statement of Operations related to the forgiveness of the debt plus accrued interest. On February 28, 2021, the Company issued an aggregate of $75 in unsecured notes, $30 to related parties and $45 to other investors. The Company received $15 in cash and $15 in exchange for an account receivable advance, received in the prior year, from related parties, and $45 in cash from other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $0.50. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $0.50 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2021. In April 2021, the Company re-paid $49 of Accounts Receivable Advances and $6 in accrued but unpaid 5% advance fees to an affiliate. In addition the Company repaid to another affiliate $64 of Accounts Receivable Advances and $4 in accrued but unpaid 5% advance fees. In June 2021, the Company paid the first installment in the amount of $40 plus accrued interest of $5 of a note entered into associated with a settlement agreement dated July 1, 2020 with one of its vendors. The remaining $90 plus interest at the rate of 4% per annum is due in two installments, June of 2022 and June of 2023. On September 30, 2021 the Company issued a note to one an affiliate investor and received $75 in cash. The note bears interest at the rate of 20% per annum and is due upon demand. During the three and nine months ended September 30, 2021, the Company accrued $84 and $243 of interest expense, $75 and $211, respectively, associated with the outstanding secured and unsecured convertible promissory notes, of which $35 and $97 was to related parties and $40 and $114 was to other investors. For the three and nine months ended September 30, 2020, the Company accrued $83 and $221 of interest expense, $73 and $194, respectively, associated with the outstanding secured and unsecured convertible promissory notes, of which $28 and $76 was to related parties and $45 and $118 was to other investors. |
Stockholders' Deficit
Stockholders' Deficit | 9 Months Ended |
Sep. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Deficit | 5. Stockholders’ Deficit Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended September 30, 2021 and 2020, was approximately 11.2% and 13.4%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. No options were granted during the three and nine months ended September 30, 2021 and 2020. There were no stock options exercised during the three and nine months ended September 30, 2021 and 2020, respectively. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three and nine-month periods ended September 30, 2021 and 2020. Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ - $ 1 $ - $ 7 General and administrative - 21 - 49 Director options 9 8 38 13 Stock-based compensation 4 - 15 - expense $ 13 $ 30 $ 53 $ 69 A summary of option activity under the Company’s plans as of September 30, 2021 and 2020 is as follows: 2021 2020 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1, 1,338 $ 0.87 $ - 1,077 $ 1.59 $ - Granted ─ $ ─ $ - 290 $ 0.50 $ - Forfeited or expired ─ $ ─ $ - (29 ) $ 23.63 $ - Outstanding at September 30 1,338 $ 0.87 $ - 1,338 $ 0.86 4.84 $ - Vested and expected to vest at September 30 1,338 $ 0.87 $ - 1,293 $ 1.40 5.15 $ - Exercisable at September 30 1,138 $ 0.94 $ - 868 $ 1.03 4.18 $ - The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2021: Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $0.01 – $25.00 1,323 3.88 $ 0.60 1,123 $ 0.60 $0.25.01 – $625 15 0.33 $ 26.81 15 26.81 Total 1,338 3.84 $ 0.89 1,138 $ 0.94 The following table summarizes the Company’s non-vested option shares as of September 30, 2021: Non-vested Option Shares Shares Weighted Non-vested at January 1, 2020 381 $0.57 Vested (181 ) $ 0.57 Non-vested at September 30, 2020 200 $ 0.50 As of September 30, 2021, there was $33 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 1.19 years. In June 2021, the Company, with approval of the Board of Directors, reallocated all of the $560,000 of accrued compensation owed to SG Phoenix in equal parts to Mr. Sassower and Mr. Goren, according to their respective ownership in SG Phoenix. Mr. Sassower settled $280,000 of Accrued Long -term deferred salary allocated to him into 560,000 shares of the Company’s Common Stock at a price of $0.50 per share, which was substantially above the then current market price of the company’s common stock. Warrants The Company did not issue any warrants during the three and six month periods ended June 30, 2021. The Company issued 30,000 warrants during the three and six months ended June 30, 2020 to a consultant for services. The warrants are exercisable for three years with an exercise price of $0.50 per share. The Company ascribed a value of $13 to the warrants which is based on the Black-Scholes-Merton valuation model. In June 2021, the Company transferred from SGP to Andrea Goren the Common Stock Purchase Warrant numbers 19-01 and 20-2, respectively dated February 6, 2019 and August 11, 2020 (the “SGP Warrants”) to purchase Seven Hundred Thousand (700,000) and Two hundred Fifty Thousand (250,000) shares of Company common stock, respectively. A summary of the warrant activity for the nine months ended September 30 is as follows: September 30, September 30, Shares Weighted Average Exercise Price Per Share Shares Weighted Average Exercise Price Per Share Outstanding at beginning of period 3,001 $ 1.52 2,536 $ 1.52 Issued ─ $ ─ 465 $ 0.50 Expired (1,551 ) $ 2.18 - $ - Outstanding at end of period 1,450 $ 0.50 3,001 $ 1.37 Exercisable at end of period 1,450 $ 0.50 3,001 $ 1.37 A summary of the status of the warrants outstanding and exercisable as of September 30, 2021 is as follows: Number of Shares Weighted Average Weighted Average 985 0.36 $ 0.50 30 1.34 $ 0.50 10 3.83 $ 0.50 425 1.89 $ 0.50 1,450 0.85 $ 0.50 |
Subsequent Event
Subsequent Event | 9 Months Ended |
Sep. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Event | 6. Subsequent Event The Company has evaluated subsequent events for potential recognition or disclosure for the period from September 30, 2021 through November 15, 2021, the date the financial statements were issued. Forward Looking Statements Certain statements contained in this quarterly report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “hopes”, “intends”, “expects”, and other words of similar import, constitute “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual events to differ materially from expectations. Such factors include those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, including the following: ● Technological, engineering, manufacturing, quality control or other circumstances that could delay the sale or shipment of products; ● Economic, business, market and competitive conditions in the software industry and technological innovations that could affect the Company’s business; ● The Company’s inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the proprietary rights of the Company; and ● General economic a nd business conditions and the availability of sufficient financing. Except as otherwise required by applicable laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, as a result of new information, future events or otherwise. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Nature of Business | Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, and Sign-it® programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. Since March 11, 2020 states in the U.S., including California, where the Company is headquartered, have begun to open up as the result of the development of vaccines to thwart the spread of the virus. New variants of COVID-19 have surfaced around the world, including the United States which may cause additional closures of economies depending on how virulent the new strains are. New COVID-19 variant outbreaks may further disrupted supply chains and affected production and sales across a wide range of industries. The extent of the impact of new COVID-19 outbreaks on our operational and financial performance will depend on certain developments, including the duration and further spread of the outbreak, continued impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. |
Basis of Presentation | Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. |
Going Concern | Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2021, the Company’s accumulated deficit was $135,564. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2021, the Company’s cash balance was $108. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. |
Accounting Changes and Recent Accounting Pronouncements | Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). A modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange should be treated as an exchange of the original instrument for a new instrument. In addition, the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity should be measured. The effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange should be recognize on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021. Early adoption is permitted for all entities, including adoption in an interim period. The Company will evaluate ASU 2021-04 to determine what impact, if any, the adoption will have on the Company’s financial statements. Other Accounting Standards Updates issued in 2021 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows. |
Concentrations (Tables)
Concentrations (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Risks and Uncertainties [Abstract] | |
Schedule of accounts receivable and revenue concentrations | Accounts Receivable Total Revenue Total Revenue 2021 2020 2021 2020 2021 2020 Customer #1 88 % 70 % 40 % 18 % 38 % 21 % Customer #2 12 % 24 % - - - - Customer #3 - - - 10 % - 11 % Customer #4 - - 18 % 21 % 19 % 23 % Customer #5 - - 23 29 % 25 % 23 % Total concentration 100 % 94 % 81 % 78 % 82 % 78 % |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of options and warrants would be antidilutive | For the September 30, 2021 September 30, 2020 Common Stock subject to outstanding options 1,338 1,338 Common Stock subject to outstanding warrants 1,450 3,001 Common stock subject to outstanding convertible debt plus accrued interest 7,290 6,608 |
Stockholders' Deficit (Tables)
Stockholders' Deficit (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Schedule of stock-based compensation expense | Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ - $ 1 $ - $ 7 General and administrative - 21 - 49 Director options 9 8 38 13 Stock-based compensation 4 - 15 - expense $ 13 $ 30 $ 53 $ 69 |
Schedule of option activity under the Company's plans | 2021 2020 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1, 1,338 $ 0.87 $ - 1,077 $ 1.59 $ - Granted ─ $ ─ $ - 290 $ 0.50 $ - Forfeited or expired ─ $ ─ $ - (29 ) $ 23.63 $ - Outstanding at September 30 1,338 $ 0.87 $ - 1,338 $ 0.86 4.84 $ - Vested and expected to vest at September 30 1,338 $ 0.87 $ - 1,293 $ 1.40 5.15 $ - Exercisable at September 30 1,138 $ 0.94 $ - 868 $ 1.03 4.18 $ - |
Schedule of significant ranges of outstanding and exercisable options | Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $0.01 – $25.00 1,323 3.88 $ 0.60 1,123 $ 0.60 $0.25.01 – $625 15 0.33 $ 26.81 15 26.81 Total 1,338 3.84 $ 0.89 1,138 $ 0.94 |
Schedule of the company's non-vested shares | Non-vested Option Shares Shares Weighted Non-vested at January 1, 2020 381 $0.57 Vested (181 ) $ 0.57 Non-vested at September 30, 2020 200 $ 0.50 |
Schedule of warrant activity | September 30, September 30, Shares Weighted Average Exercise Price Per Share Shares Weighted Average Exercise Price Per Share Outstanding at beginning of period 3,001 $ 1.52 2,536 $ 1.52 Issued ─ $ ─ 465 $ 0.50 Expired (1,551 ) $ 2.18 - $ - Outstanding at end of period 1,450 $ 0.50 3,001 $ 1.37 Exercisable at end of period 1,450 $ 0.50 3,001 $ 1.37 |
Schedule of warrants outstanding and exercisable | Number of Shares Weighted Average Weighted Average 985 0.36 $ 0.50 30 1.34 $ 0.50 10 3.83 $ 0.50 425 1.89 $ 0.50 1,450 0.85 $ 0.50 |
Nature of Business and Summar_2
Nature of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Accounting Policies [Abstract] | ||
Accumulated deficit | $ (135,564) | $ (135,203) |
Cash | $ 108 |
Concentrations (Details) - Sche
Concentrations (Details) - Schedule of accounts receivable and revenue concentrations - Customer Concentration Risk [Member] | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 100.00% | 94.00% | ||
Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 81.00% | 78.00% | 82.00% | 78.00% |
Customer #1 [Member] | Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 88.00% | 70.00% | ||
Customer #1 [Member] | Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 40.00% | 18.00% | 38.00% | 21.00% |
Customer #2 [Member] | Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 12.00% | 24.00% | ||
Customer #2 [Member] | Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | ||||
Customer #3 [Member] | Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | ||||
Customer #3 [Member] | Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 10.00% | 11.00% | ||
Customer #4 [Member] | Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | ||||
Customer #4 [Member] | Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 18.00% | 21.00% | 19.00% | 23.00% |
Customer #5 [Member] | Accounts Receivable [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | ||||
Customer #5 [Member] | Total Revenue [Member] | ||||
Variable Interest Entity [Line Items] | ||||
Total concentration | 23.00% | 29.00% | 25.00% | 23.00% |
Net Loss Per Share (Details) -
Net Loss Per Share (Details) - Schedule of options and warrants would be antidilutive - shares shares in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2021 | Sep. 30, 2020 | |
Schedule of options and warrants would be antidilutive [Abstract] | ||
Common Stock subject to outstanding options | 1,338 | 1,338 |
Common Stock subject to outstanding warrants | 1,450 | 3,001 |
Common stock subject to outstanding convertible debt plus accrued interest | 7,290 | 6,608 |
Debt (Details)
Debt (Details) - USD ($) $ in Thousands | May 06, 2020 | Sep. 30, 2021 | Aug. 31, 2021 | Jul. 31, 2021 | Jun. 30, 2021 | Apr. 30, 2021 | Feb. 28, 2021 | Feb. 22, 2021 | Feb. 17, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Apr. 01, 2021 | Mar. 31, 2021 |
Debt Disclosure [Abstract] | |||||||||||||||
Advance accounts receivable | $ 49 | $ 30 | $ 30 | $ 64 | |||||||||||
Accrued advances unpaid | $ 6 | $ 4 | $ 4 | ||||||||||||
Accounts receivable advances repaid | $ 20 | ||||||||||||||
Advance fee | $ 1 | 1 | |||||||||||||
Accounts receivable advances in cash | $ 25 | ||||||||||||||
Advance fee, percentage | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||
Received cash from affiliates | $ 36,000 | $ 50,000 | $ 10,000 | ||||||||||||
Account receivable description | The company accrued a 5% advance fee and recorded $500 as interest expense during the three months ended September 30, 2021. Upon collection of the accounts receivable the Company will repay the advance plus the 5% fee. | ||||||||||||||
Interest expense | $ 4 | ||||||||||||||
Advance fees | 5.00% | ||||||||||||||
Notes payable, description | the Company received loan proceeds in the amount of approximately $123 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Company may apply for the loans and accrued interest forgiven after a period of either eight or twenty-four weeks, as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the period in question. Under the terms of the related promissory note, the unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. | the Company issued an aggregate of $75 in unsecured notes, $30 to related parties and $45 to other investors. The Company received $15 in cash and $15 in exchange for an account receivable advance, received in the prior year, from related parties, and $45 in cash from other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $0.50. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $0.50 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2021. | |||||||||||||
Other income | $ 125 | ||||||||||||||
Accrued unpaid percentage | 5.00% | 5.00% | |||||||||||||
First installment | $ 40 | ||||||||||||||
Accrued interest expense | $ 5 | $ 84 | $ 83 | $ 221 | |||||||||||
Interest rate percentage | 4.00% | 4.00% | 4.00% | ||||||||||||
Cash received from investor | $ 75 | $ 75 | $ 75 | ||||||||||||
Interest rate | 20.00% | 20.00% | 20.00% | ||||||||||||
Accrued interest expense | $ 243 | ||||||||||||||
Interest expense | $ 75 | 73 | 211 | 194 | |||||||||||
Convertible promissory notes | 35 | 28 | 97 | 76 | |||||||||||
Outstanding to related parties | $ 40 | $ 45 | $ 114 | $ 118 |
Stockholders' Deficit (Details)
Stockholders' Deficit (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 9 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Stockholders' Equity Note [Abstract] | |||||
Percentage of estimated average forfeiture rate | 11.20% | 13.40% | |||
Total unrecognized compensation expense | $ 33 | ||||
Weighted average period | 1 year 2 months 8 days | ||||
Accrued Compensation amount | $ 560,000 | ||||
Accrued long term deferred salary | $ 280,000 | ||||
Number of share (in Shares) | 560,000 | ||||
Common stock price per share (in Dollars per share) | $ 0.5 | ||||
Issued warrants (in Shares) | 30,000 | 30,000 | |||
Warrants exercisable years | 3 years | ||||
Exercise price (in Dollars per share) | $ 0.5 | ||||
Warrants amount | $ 13 |
Stockholders' Deficit (Detail_2
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items] | ||||
Total expense | $ 13 | $ 30 | $ 53 | $ 69 |
Stock-Based Compensation [Member] | ||||
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items] | ||||
Total expense | 4 | 15 | ||
Research and Development [Member] | ||||
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items] | ||||
Total expense | 1 | 7 | ||
General and Administrative [Member] | ||||
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items] | ||||
Total expense | 21 | 49 | ||
Director Options [Member] | ||||
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items] | ||||
Total expense | $ 9 | $ 8 | $ 38 | $ 13 |
Stockholders' Deficit (Detail_3
Stockholders' Deficit (Details) - Schedule of option activity under the Company's plans - Option [Member] - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Stockholders' Deficit (Details) - Schedule of option activity under the Company's plans [Line Items] | ||
Shares, Outstanding at beginning | 1,338,000 | 1,590 |
Weighted Average Exercise Price per share, outstanding at beginning | $ 0.87 | |
Weighted Average Remaining Contractual Term (Years), outstanding at beginning | ||
Aggregate Intrinsic Value, outstanding at beginning | $ 1,077 | |
Shares, Granted | 500 | |
Weighted Average Exercise Price Per Share, Granted | ||
Weighted Average Remaining Contractual Term (Years), Granted | ||
Aggregate Intrinsic Value, Granted | $ 290 | |
Shares, Forfeited or expired | 23,630 | |
Weighted Average Remaining Contractual Term (Years), Forfeited or expired | ||
Aggregate Intrinsic Value, Forfeited or expired | $ (29) | |
Shares, outstanding at ending | 1,338,000 | 860 |
Weighted Average Exercise Price per share, outstanding at ending | $ 0.87 | $ 4.84 |
Weighted Average Remaining Contractual Term (Years), outstanding at ending | ||
Aggregate Intrinsic Value, outstanding at ending | $ 1,338 | |
Shares, Vested and expected to vest | 1,338,000 | 1,400 |
Weighted Average Exercise Price per share, Vested and expected to vest | $ 0.87 | $ 5.15 |
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest | ||
Aggregate Intrinsic Value, Vested and expected to vest | $ 1,293 | |
Shares, Exercisable | 1,138,000 | 1,030 |
Weighted Average Exercise Price per share, Exercisable | $ 0.94 | $ 4.18 |
Weighted Average Remaining Contractual Term (Years), Exercisable | ||
Aggregate Intrinsic Value, Exercisable | $ 868 |
Stockholders' Deficit (Detail_4
Stockholders' Deficit (Details) - Schedule of significant ranges of outstanding and exercisable options shares in Thousands | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Options Outstanding, Number Outstanding | shares | 1,338 |
Options Outstanding, Weighted Average Remaining Contractual Life (in years) | 3 years 10 months 2 days |
Options Outstanding, Weighted Average Exercise Price Per Share | $ / shares | $ 0.89 |
Options Exercisable, Number Outstanding | shares | 1,138 |
Options Exercisable, Weighted Average Exercise Price Per Share | $ / shares | $ 0.94 |
$0.01 – $25.00 [Member] | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Options Outstanding, Number Outstanding | shares | 1,323 |
Options Outstanding, Weighted Average Remaining Contractual Life (in years) | 3 years 10 months 17 days |
Options Outstanding, Weighted Average Exercise Price Per Share | $ / shares | $ 0.6 |
Options Exercisable, Number Outstanding | shares | 1,123 |
Options Exercisable, Weighted Average Exercise Price Per Share | $ / shares | $ 0.6 |
$0.25.01 – $625 [Member] | |
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Options Outstanding, Number Outstanding | shares | 15 |
Options Outstanding, Weighted Average Remaining Contractual Life (in years) | 3 months 29 days |
Options Outstanding, Weighted Average Exercise Price Per Share | $ / shares | $ 26.81 |
Options Exercisable, Number Outstanding | shares | 15 |
Options Exercisable, Weighted Average Exercise Price Per Share | $ / shares | $ 26.81 |
Stockholders' Deficit (Detail_5
Stockholders' Deficit (Details) - Schedule of the company's non-vested shares | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Schedule of the company's non-vested shares [Abstract] | |
Shares, Non-vested at beginning | shares | 381,000 |
Weighted Average Grant-Date Fair Value, Shares | $ / shares | $ 0.57 |
Shares, Vested | shares | (181,000) |
Weighted Average Grant-Date Fair Value, Vested | $ / shares | $ 0.57 |
Shares, Non-vested at ending | shares | 200,000 |
Weighted Average Grant-Date Fair Value, Non-vested at ending | $ / shares | $ 0.5 |
Stockholders' Deficit (Detail_6
Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - $ / shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items] | ||
Shares Outstanding at beginning of period | 3,001 | 2,536 |
Weighted Average Exercise Price Per Share, Outstanding at beginning of period | $ 1.52 | $ 1.52 |
Shares, Issued | 465 | |
Weighted Average Exercise Price Per Share, Issued | $ 0.5 | |
Shares, Expired | (1,551) | |
Weighted Average Exercise Price Per Share, Expired | $ 2.18 | |
Shares, Outstanding at end of period | 1,450 | 3,001 |
Weighted Average Exercise Price Per Share, Outstanding at end of period | $ 0.5 | $ 1.37 |
Shares, Exercisable at end of period | 1,450 | 3,001 |
Weighted Average Exercise Price Per Share, Exercisable at end of period | $ 0.5 | $ 1.37 |
Stockholders' Deficit (Detail_7
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable shares in Thousands | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items] | |
Number of Shares Issuable Under Warrants | shares | 1,450 |
Weighted Average Remaining Life (years) | 10 months 6 days |
Weighted Average Exercise Price per share | $ / shares | $ 0.5 |
Warrants Group One [Member] | |
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items] | |
Number of Shares Issuable Under Warrants | shares | 985 |
Weighted Average Remaining Life (years) | 4 months 9 days |
Weighted Average Exercise Price per share | $ / shares | $ 0.5 |
Warrants Group Two [Member] | |
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items] | |
Number of Shares Issuable Under Warrants | shares | 30 |
Weighted Average Remaining Life (years) | 1 year 4 months 2 days |
Weighted Average Exercise Price per share | $ / shares | $ 0.5 |
Warrants Group Three [Member] | |
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items] | |
Number of Shares Issuable Under Warrants | shares | 10 |
Weighted Average Remaining Life (years) | 3 years 9 months 29 days |
Weighted Average Exercise Price per share | $ / shares | $ 0.5 |
Warrants Group Four [Member] | |
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items] | |
Number of Shares Issuable Under Warrants | shares | 425 |
Weighted Average Remaining Life (years) | 1 year 10 months 20 days |
Weighted Average Exercise Price per share | $ / shares | $ 0.5 |